Breast-specific gamma imaging (BSGI) provided high sensitivity for the detection of atypical, high-risk breast lesions, which could help physicians identify candidates for preventive treatment, according to a study published in the June issue of Academic Radiology.
Naviscan PET scanners performing positron emission mammography (PEM) have been installed in two European centers: Radiologie und Nuklearmedizin in Ludwigshafen, Germany, and Medica in Istanbul, Turkey.
Women with two types of high-risk lesions (papilloma and radial scar) with normal MRI results can avoid surgical excision and instead undergo clinical and imaging follow-up, according to a prospective study published in the February issue of American Journal of Roentgenology.
University of Texas (UT) Southwestern Medical Center in Dallas has installed a PET scanner, the breast application for which is positron emission mammography (PEM), which will be used both for clinical patients as well as for research focused on lowering radiation dose and novel radiotracers.
Women diagnosed with breast cancer are increasingly burdened by multiple imaging appointments prior to surgery, according to researchers from Fox Chase Cancer Center in Philadelphia, who presented the findings Dec. 9 at the San Antonio Breast Cancer Symposium.
The final diagnostic form the evolving hybrid PET/MR tree will take is uncertain, but it has already begun to blossom. Thus, the low-hanging clinical fruit has lured a number of medical centers to early adoption. Experts weigh in on the potential that PET/MR may hold for various neurologic, oncologic and cardiovascular conditions.
Molecular breast imaging is proving its worth as an low-dose alternative to MRI for women with dense breasts. Sponsored by an educational grant from Gamma Medica
Breast imaging reports generated using speech recognition were eight times as likely as reports dictated with conventional transcription to contain major errors, according to a study published in the October issue of American Journal of Roentgenology. The researchers estimated that nearly 25 percent of the reports in the study contained a major error that could have affected understanding of the report or altered patient care.
A nationwide U.S. survey found that women overwhelmingly want the option for additional screening tests to find cancer early, even when testing resulted in a false positive. Nine out of 10 women who required a biopsy to determine a false positive indicated that they would still opt for the additional screening the following year.
Dilon Diagnostics has formed a sales alliance with PenRad, in which Dilon is expanding its portfolio to include the PenRad Mammography Information System (MIS), and Volpara, a quantitative breast density assessment tool that converts the qualitative breast x-ray image into quantitative data.
Dilon Diagnostics has launched its FDA-cleared Dilon 6800 Acella Gamma Camera system.
|
|
|
|
RSS 
